A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
NCT ID: NCT06106022
Last Updated: 2024-12-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
22 participants
INTERVENTIONAL
2023-11-01
2024-04-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vonoprazan 10mg
Participants will receive vonoprazan 10mg QD for 14 days.
Vonoprazan
Administered orally
Vonoprazan 20mg
Participants will receive vonoprazan 20mg QD for 14 days.
Vonoprazan
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vonoprazan
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The participant must have a diagnosis of GERD prior to randomization and medical history of signs or symptoms of GERD for at least 3 months prior to screening, based on physical examination, current symptoms (eg, heartburn), or diagnostic tests (eg, pH or endoscopy). Notes in the medical records and/or other source documents, such as prior endoscopies, can be used to support the diagnosis and will be recorded in the electronic case report form (eCRF).
3. The participant has at least one moderate GERD symptom based on the GERD Symptom Assessment Investigator scale performed at screening.
4. The participant must be able to swallow study drug tablet with water.
5. Parent or legal guardian (ie, legally authorized representative \[LAR\]) is willing and able to complete the informed consent process and participants are able to comply with study procedures and visit schedule.
6. Female participants who have experienced menarche must have a negative pregnancy test and will be counseled on pregnancy avoidance.
Exclusion Criteria
2. The participant has used sucralfate, or antacids within 1 day prior to randomization or requires their use during the Treatment Period.
3. The participant has received other agents affecting digestive organs, including muscarinic antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the course of the study.
4. The participant has received atazanavir sulfate or rilpivirine hydrochloride from 5 days prior to Day 1 or requires their use during the course of the study.
5. The participant has received any investigational compound (including vonoprazan) within 30 days prior to the start of the Screening Period.
6. The participant is an immediate family member or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, child, sibling) or participant may have consented under duress.
7. The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Period.
8. The participant has undergone prior gastrointestinal surgeries.
9. The participant has any abnormal laboratory test values that are considered clinically significant in the opinion of the investigator during the Screening Period.
10. The participant has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients: D-mannitol, microcrystalline cellulose, hydroxypropylcellulose, fumaric acid, ascorbic acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, and titanium dioxide, or red or yellow ferric oxide).
11. The participant has used any prescription or over-the-counter medications (including herbal or nutritional supplements), other than those already excluded in criteria 1 to 5 above, within 14 days before the first dose of study drug or throughout the study. That is, unless the medication(s) is permitted by the sponsor following a review of available data which confirms concomitant administration of the medication is unlikely to affect either the safety of the participant or the pharmacokinetics of vonoprazan.
12. The participant has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family \[kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard\] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout the study.
13. The participant has positive results at screening for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus (HCV).
14. The participant has severe renal impairment (estimated glomerular filtration rate \< 30 mL/min).
15. The participant has moderate to severe hepatic impairment (Child-Pugh Class B and Child-Pugh Class C).
16. The participant has any of the following abnormal laboratory test values at the start of the Screening Period:
1. Creatinine levels: \>0.8 mg/dL (\>70 μmol/L).
2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2 × the upper limit of normal (ULN) or total bilirubin \>2 × ULN (except participants with Gilbert Syndrome).
17. In the opinion of the investigator, the participant is not suitable for entry into the study.
6 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Phathom Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Strada Patient Care Center
Mobile, Alabama, United States
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Med Research Associates, Inc
Hollywood, Florida, United States
Avanza Medical Research Center
Pensacola, Florida, United States
International Center for Research
Tampa, Florida, United States
Children's Center for Digestive Health Care, LLC
Atlanta, Georgia, United States
Riley Hospital for Children at IU Health
Indianapolis, Indiana, United States
Tandem Clinical Research GI, LLC
Marrero, Louisiana, United States
Advantage Clinical Trials
The Bronx, New York, United States
PriMED Clinical Research
Dayton, Ohio, United States
Cyn3rgy Research
Gresham, Oregon, United States
Maspons Pediatric Gastro
El Paso, Texas, United States
Stryde Research - NxT Step Pediatrics
Frisco, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-003228-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
VPED-103
Identifier Type: -
Identifier Source: org_study_id